EANS-News: SYGNIS Pharma AG / Shareholders support management proposals at SYGNIS Pharma´s AGM with overwhelming majority

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Annual & Special Corporate Meetings

Heidelberg (euro adhoc) - Shareholders support management proposals
at SYGNIS Pharma´s AGM with overwhelming majority

Heidelberg, 25 November 2011 - At today´s Annual General Meeting
(AGM) of SYGNIS Pharma AG (Frankfurt: LIOK; ISIN
DE000A1E9B74; Prime Standard) shareholders representing about
73 percent of the capital approved all proposals of the
Management with an overwhelming majority. Main decisions were
related to the discharge of the members of the Supervisory and the
Management Board for the past Fiscal Year, the election of the
members of the Supervisory Board as well as the creation of
contingent capital for convertible bonds.

All members of the Supervisory Board have been re-elected, with the
exception of Mr. Friedrich Christ. Mr. Christ has meanwhile
retired and it was his personal decision not to stand for
re-election. From today´s AGM onwards, Dr. Wolf-Dieter Starp,
Head of Global M&A at BASF SE, has been elected to the
Supervisory Board.

Prof. Dr. Friedrich von Bohlen und Halbach, chairman of the
Supervisory Board thanked Mr. Christ for his work and efforts during
the last years for SYGNIS Pharma AG. He welcomed Dr. Starp as a
new member of the Supervisory Board.

At the AGM the two members of the Management Board, Peter
Willinger and Dr. Frank Rathgeb, confirmed that the data on SYGNIS´
current AXIS 2 efficacy study for AX200 for the treatment of acute
stroke is expected to be published in December 2011.

About SYGNIS Pharma SYGNIS Pharma AG, headquartered in Heidelberg,
is a specialty pharmaceutical company listed on the Prime Standard
of the German stock exchange. The Company is focused on the
research, development and marketing of innovative therapies for
the treatment of disorders of the Central Nervous System. These
include Stroke, Amyotrophic Lateral Sclerosis and neurological
disorders resulting from injuries to the brain or spinal cord. All
these disorders are characterized by the fact that, as the disease
progresses, nerve cells are damaged and die. Although there is
great medical demand, there are currently no or only
inadequate treatment options available.

For further information please contact:
SYGNIS Pharma AG:

|Dr. Franz-Werner Haas |
|Senior Vice President Operations |
|+49 (0) 6221 454 812 |
|franz-werner.haas@sygnis.de |

Media-Contact:
Julia Phillips
FTI Consulting
Tel.: +44 (0) 20 7269 7187

### Disclaimer Some statements included in this press release,
relating neither to proven financial results nor other historical
data, should be viewed as forward- looking, i.e. not definite.
Such statements are mainly predictions of future results, trends,
plans or goals. These statements should not be considered to be
total guarantees since given their very nature they are subject to
known and unknown risks and imponderability and can be affected by
other factors as a consequence of which the actual results, plans
and goals of SYGNIS Pharma AG may deviate greatly from the
established conclusions or implied predictions contained in such
statements. SYGNIS does not undertake to publicly update or revise
these statements in the light of new information or future results
or for any other reason. ###

Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail: Michael.Wolf@sygnis.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: SYGNIS Pharma AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 (0)6221 454-6
FAX: +49 (0)6221 454-777
mail: contact@sygnis.de
WWW: http://www.sygnis.de
sector: Biotechnology
ISIN: DE000A1E9B74
indexes: CDAX, Prime All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Hamburg, Stuttgart, Düsseldorf, Hannover, München
language: English